Division of Rheumatology and Clinical Immunology, Division of Pediatric Rheumatology, University of Pittsburgh, Children's Hospital, Suite 3000, 400 45th Street, Pittsburgh, PA 15201, USA.
Expert Rev Clin Immunol. 2010 Nov;6(6):855-66. doi: 10.1586/eci.10.69.
The past decade has been an exciting period for clinical research and patient care in rheumatoid arthritis. This is mostly due to targeted biologic agents that have changed the outcome of this disease. Certolizumab pegol (Cimzia(®), UCB Inc., GA, USA), which targets TNF-α with a different mechanism of action than widely used biologics, was initially investigated for Crohn's disease but has now been shown to be effective for rheumatoid arthritis. There have been three significant clinical trials demonstrating the efficacy of certolizumab pegol in active rheumatoid arthritis; two with combination methotrexate and one with monotherapy. This article will summarize the data from those trials and compare some of the characteristics of certolizumab pegol to conventional disease-modifying antirheumatic drugs and other biologic agents. Treatment recommendations are beyond the scope of this review; however, with many options available, there will be annotations on current trends in the care of this chronic disease.
过去十年是类风湿关节炎临床研究和患者治疗的激动人心的时期。这主要是由于靶向生物制剂改变了这种疾病的结局。培塞利珠单抗（Cimzia ® ，UCB Inc.，GA，美国）通过与广泛使用的生物制剂不同的作用机制靶向 TNF-α，最初被用于治疗克罗恩病，但现已被证明对类风湿关节炎有效。有三项重要的临床试验证明了培塞利珠单抗在活动性类风湿关节炎中的疗效；其中两项与甲氨蝶呤联合治疗，一项为单药治疗。本文将总结这些试验的数据，并将培塞利珠单抗的一些特征与传统的疾病修饰抗风湿药物和其他生物制剂进行比较。治疗建议超出了本综述的范围；然而，有许多可供选择的方案，因此将对这种慢性疾病护理的当前趋势进行注释。
